Search
XTL-6865
go.drugbank.com/drugs/DB06058InvestigationalIt is being developed to prevent HCV re-infection following a liver transplant and for the treatment of chronic HCV disease. … XTL-6865 is a combination of two fully human monoclonal antibodies (Ab68 and Ab65) against the hepatitis C virus E2 envelope protein.
Ulimorelin
go.drugbank.com/drugs/DB12128InvestigationalUlimorelin is a novel small molecule ghrelin agonist being developed by Tranzyme Pharma as a first-in-class treatment for both POI and diabetic gastroparesis, serious medical conditions in which motility
AT1391
go.drugbank.com/drugs/DB05120ExperimentalAT1391 is a daily insulin skin patch designed to provide continuous basal levels of insulin for patients with diabetes.
ABT-510
go.drugbank.com/drugs/DB05434InvestigationalIt is developed by Abbott Laboratories for the treatment of Solid Tumors, Lymphoma and Melanoma.
Pentaglobin
go.drugbank.com/drugs/DB15865Investigational[A220173] It is comprised of [immunoglobulin G (IgG)](https://www.drugbank.ca/drugs/DB00028) and immunoglobulin A (IgA) while also being enriched by immunoglobulin M (IgM).[L16353]
Methyprylon
go.drugbank.com/drugs/DB01107ApprovedIllicitWithdrawnMethyprylon was withdrawn from the U.S. market in June 1965 and the Canadian market in September 1990 due to adverse events.
PLT012
go.drugbank.com/drugs/DB23610InvestigationalPLT012 is a humanized anti-CD36 antibody developed by Pilatus Biosciences for treating liver cancer and intrahepatic bile duct cancer.